Demonstration of an Association between Chlamydia pneumoniae Infection and Venous Thromboembolic Disease

Summary

Chlamydia pneumoniae infection has been linked to atherosclerosis, but a possible relationship with venous thromboembolism (VTE) has not been sought. We determined circulating anti-C. pneumoniae antibody levels in patients with VTE. We studied 176 case patients with objectively diagnosed VTE and 197 age-and sex-matched healthy controls, in a retrospective study. Acquired risk factors for VTE and frequent predisposing genetic factors (factor V Arg 506 Gln and factor II G 20210 A mutations) were assessed in all the subjects. Anti-C. pneumoniae IgG antibodies were determined by microimmunofluorescence. All positive plasma samples (titer ≥128) were precisely quantified and tested for the presence of specific IgM antibodies. Fiftyfour percent of the cases and 15.9% of the controls had specific IgG titers of at least 256 (p <0.0001). The crude odds ratio for VTE was 6.2 (95% CI, 3.8-10.1), and rose to 7.7 (4.5-13.2) after excluding subjects carrying the factor V Arg 506 Gln or factor II G 20210 A mutations. The odds ratio for VTE increased with the IgG titer: the adjusted odds ratios were 2.1 (95% CI, 1.1-4.1), 5.3 (2.7-10.6) and 33.0 (4.4-248.4) for titers of 256, 512 and 1024, respectively. Only one subject (a case patient) with a high IgG titer (≥256) also had specific IgM. High titers of anti-C. pneumoniae IgG antibodies are frequently found in patients with previous venous thromboembolism. This association deserves to be confirmed in other case-control studies and prospective studies.

All authors have reviewed the manuscript and agree with its content.

Keywords

Deep vein thrombosis - pulmonary embolism - venous thromboembolism - chlamydia pneumoniae - thrombosis

• References

• 1 Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78: 1-6.
• 2 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
• 3 Bertina RM, Koeleman BPC, Koster T, Rosenddal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 4 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 5 Mateo J, Oliver A, Bonel M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism. Results of the Spanish multicenter study on thrombophilia (EMET-study). Thromb Haemost 1997; 77: 444-51.
• 6 Schwartz A. Phlébites. Brissaud E, Pinard A, Reclus P. (eds) Pratique médico-chirurgicale, Paris, Masson. 1907: 280.
• 7 Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet 1997; 350: 430-6.
• 8 Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. Circulation 1997; 96: 4095-103.
• 9 Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infection and stroke. Clin Inf Dis 1998; 26: 719-34.
• 10 Gibbs RGJ, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg 1998; 85: 1191-7.
• 11 Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-4.
• 12 Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psitacci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315: 161-8.
• 13 Saikku P, Mattila K, Nieminen MS, Huttunen JK, Leinonen M, Ekman MR, Mäkelä PH, Valtonen V. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii: 983-5.
• 14 Grayston JT, Kuo C-C, Campbell LA, Benditt EP. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur Heart J 1993; 14 (suppl K) 66-71.
• 15 Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor-Robinson D. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996; 49: 102-6.
• 16 Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, Emmerich J. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-10.
• 17 Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coag Fibrinol 1995; 6: 245-9.
• 18 Woods GL, Walker DH. Chlamydial, rickettsial, and mycoplasmal infections. Henry JB. (ed) Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia: Saunders; 1996: 1115.
• 19 Davidson M, Kuo C-C, Middaugh JP, Campbell LA, Wang SP, Newman WP, Finley JC, Grayston T. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998; 98: 628-33.
• 20 Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Mänttäri M, Frick H, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-8.
• 21 Ossewaarde JM, Feskens EJM, De Vries A, Vallinga CE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998; 120: 93-9.
• 22 Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
• 23 Hu H, Piercce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae . J Clin Invest 1999; 103: 747-53.
• 24 Salzman EW, Hirsh J. The epidemiology, pathogenesis and natural history of venous thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) Hemostasis and thrombosis: basic principles and clinical practice. third ed. Philadelphia: Lippincott; 1994: 1275.
• 25 Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-7.
• 26 Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999; 283: 1335-9.
• 27 Mayr M, Metzler B, Kiechl S, Willeit J, Schett G, Xu Q, Wick G. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae. Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999; 99: 1560-6.
• 28 Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-32.
• 29 Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-Georges F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
• 30 Giesen PLA, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-15.
• 31 Koster T, Blann AD, Briet E, Vandenbroucker JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deepvein thrombosis. Lancet 1995; 345: 152-5.
• 32 Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
• 33 Nieto FJ, Sorlie P, Comstock GW, Wu K, Adam E, Melnick JL, Szklo M. Cytomegalovirus infection, lipoprotein(a), and hypercoagulability: an atherogenic link?. Arterioscl Thromb Vasc Biol 1997; 17: 1780-5.
• 34 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 35 Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. for the ROXIS study group, randomized trial of roxithromycin in non-Q-wave coronary syndrome: ROXIS pilot study. Lancet 1997; 350: 404-7.
• 36 Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.